Sulfacetamide Sodium and Sulfur

Manufacturer
Bi-Coastal Pharma International LLC
Effective date
2022-01-18
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
full-release
Hydrated at
2026-05-31 20:39:00

Label at a glance#

ProductSulfacetamide Sodium and Sulfur
Active ingredientSULFACETAMIDE SODIUM, SULFUR
Label structure11 sections

Dosage and administration

Use once daily or as directed by your physician. Wet skin. Apply in a film to entire face, avoiding contact with eyes or mucous membranes. Wait 10 minutes or until dry. Rinse thoroughly with water and pat dry.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Sulfacetamide Sodium is a sulfonamide with antibacterial activity while Sulfur acts as a keratolytic agent. Chemically Sulfacetamide Sodium is N-[(4-aminophenyl) sulfonyI]-acetamide, monosodium salt, monohydrate. The structural formula is:

Chemical Structure
Chemical Structure

Each gram of Sulfacetamide Sodium USP 10% and Sulfur USP 5% contains 100 mg of Sodium Sulfacetamide USP and 50 mg of Sulfur USP in a cream containing: Aloe Barbadensis (Aloe Vera) Leaf Extract, Butylated Hydroxytoluene, Camellia Oleifera (Green Tea) Leaf Extract, Cetyl Alcohol, Disodium Oleamido MEA Sulfosuccinate, Edetate Disodium, Fragrance, Glycerin, Glyceryl Monostearate, Magnesium Aluminum Silicate, Methylparaben, PEG-100 Stearate, Propylparaben, Purified Water, Sodium Cocoyl Isethionate, Sodium Methyl Cocoyl Taurate, Sodium Thiosulfate, Stearyl Alcohol, Xanthan Gum.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

The most widely accepted mechanism of action of sulfonamides is the Woods-Fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (PABA), an essential component for bacterial growth. While absorption through intact skin has not been determined, sulfacetamide Sodium is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine, largely unchanged. The biological half-life has variously been reported as 7 to 12.8 hours. The exact mode of action of Sulfur in the treatment of acne is unknown, but it has been reported that it inhibits the growth of Propionibacterium acnes and the formation of free fatty acids.

INDICATIONS

INDICATIONS & USAGE SECTION

Sulfacetamide Sodium and Sulfur cleanser is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Sulfacetamide Sodium and Sulfur cleanser is contraindicated for use by patients having known hypersensitivity to sulfonamides, Sulfur or any other component of this preparation. Sulfacetamide Sodium and Sulfur cleanser is not to be used by patients with kidney disease.

WARNINGS

WARNINGS SECTION

Although rare, sensitivity to Sulfacetamide Sodium may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice, and contact dermatitis indicate hypersensitivity to sulfonamides. Particular caution should be employed if areas of denuded or abraded skin are involved.

FOR EXTERNAL USE ONLY. Keep away from eyes. Keep out of reach of children. Keep container tightly closed.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

lf irritation develops, use of the product should be discontinued and appropriate therapy instituted. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. The object of this therapy is to achieve desquamation without irritation, but Sulfacetamide Sodium and Sulfur can cause reddening and scaling of the epidermis. These side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs, rinse with water. If excessive irritation develops, discontinue use and consult your physician.

Carcinogenesis, Mutagenesis and Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Longterm studies in animals have not been performed to evaluate carcinogenic potential.

Pregnancy

PREGNANCY SECTION

Category C

SPL UNCLASSIFIED SECTION

Animal reproduction studies have not been conducted with Sulfacetamide Sodium and Sulfur lotion. It is also not known whether Sulfacetamide Sodium and Sulfur cleanser can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sulfacetamide Sodium and Sulfur cleanser should be given to a pregnant woman only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether sulfacetamide sodium is excreted in the human milk following topical use of Sulfacetamide Sodium and Sulfur lotion. However, small amounts of orally administered sulfonamides have been reported to be eliminated in human milk. In view of this and because many drugs are excreted in human milk, caution should be exercised when Sulfacetamide Sodium and Sulfur cleanser is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in children under the age of 12 have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Although rare, Sulfacetamide Sodium may cause local irritation.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Use once daily or as directed by your physician. Wet skin. Apply in a film to entire face, avoiding contact with eyes or mucous membranes. Wait 10 minutes or until dry. Rinse thoroughly with water and pat dry.

HOW SUPPLIED

HOW SUPPLIED SECTION

Sulfacetamide Sodium 10% and Sulfur 5% cleanser is supplied in
6 oz (170 g) tube       NDC 42582-600-23
12 oz (340 g) bottle   NDC 42582-600-20

STORAGE AND HANDLING SECTION

Store at 20°-25°C (68°-77°F), excursions permitted between 15°-30°C (59°-86°F). Brief exposure to temperatures up to 40° (104°F) may be tolerated provided the mean kinetic temperature does not exceed 25°C (77°F); however such exposure should be minimized. Protect from freezing.

SPL UNCLASSIFIED SECTION

Call your doctor about side effects. You may report side effects to FDA at 1-800-FDA-1088.

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN

Rx Only

Manufactured for:
Bi-Coastal Pharma International LLC
Shrewsbury, New Jersey 07702 USA

PRINCIPAL DISPLAY PANEL - 340 g Bottle Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC # 42582-600-20

Sodium
Sulfacetamide
10% &
Sulfur 5%
Cleanser

For topical use only • Not
for ophthalmic use

Rx Only

Bi-Coastal Pharma International LLC

NET WT. 12 OZ. (340g)

PRINCIPAL DISPLAY PANEL - 340 g Bottle Carton
PRINCIPAL DISPLAY PANEL - 340 g Bottle Carton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
999613sulfacetamide sodium 10 % / sulfur 5 % Medicated Liquid SoapPSN3
999613sulfacetamide sodium 100 MG/ML / sulfur 50 MG/ML Medicated Liquid SoapSCD3
999613sulfacetamide sodium 10 % / sulfur 5 % Medicated Liquid SoapSY3
999613sulfacetamide sodium 10 % / sulfur 5 % Topical CleanserSY3

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
SULFACETAMIDE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
4073022c-5d5d-48f5-82ed-091ad146a4b2Product name120171211
9ffbd0ae-0bce-c086-b707-f0da5f8cd7c5Product name120150828
0304b7d2-7a07-d53b-750f-36012ae6612eProduct name120140508
64c0cc7e-6478-3ca1-8cd7-9a1251d5a3f6Product name120140508
9ae74339-0a3d-82e9-5dd1-88bd2607bd6bProduct name120140508
e44e38a9-2d9e-b0e2-cce9-490554639f3dProduct name120140508

FDA-Initiated Inactive NDC Indexing#

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
42582-600-20Sulfacetamide Sodium and Sulfur340 g in 1 BOTTLECREAM3403
42582-600-20Sulfacetamide Sodium and Sulfur1 in 1 CARTONCREAM13
42582-600-23Sulfacetamide Sodium and Sulfur170 g in 1 TUBECREAM1703
42582-600-23Sulfacetamide Sodium and Sulfur1 in 1 CARTONCREAM13

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
42582-600SULFACETAMIDE SODIUM AND SULFUR CREAM [BI-COASTAL PHARMA INTERNATIONAL LLC]3Legacy NDC, 4 package rows20220118_6bea7c93-a01b-4a67-a8a1-7779c656d945.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
42582-600-20GM - Gram42582-600356d64bb-ea19-4fe0-8fa6-a54cbbe9c4d812016-02-04
42582-600-23GM - Gram42582-60057cf4314-fa94-43cb-923b-2f8de3dc344d12016-02-04

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 22 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
42582-60042582-600-23, 42582-600-20

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 20 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ebe04d90-86e0-4d29-b66e-056771602a406bea7c93-a01b-4a67-a8a1-7779c656d9452022-01-18Warnings, Adverse reactionsExact identifier
spl id: ebe04d90-86e0-4d29-b66e-056771602a40
spl set id: 6bea7c93-a01b-4a67-a8a1-7779c656d945

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.